Posted by Michael Wonder on 31 Jul 2023
Bavencio gets coverage as first-line maintenance therapy for urothelial cancer
25 July 2023 - Merck’s anti-PD-L1 immuno-oncology drug Bavencio (avelumab) will get insurance coverage starting next month as first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed on platinum-based chemotherapy.
HIRA said Monday it put the decision to prior notice and would gather opinions until Thursday.
